Elizabeth Pando Rau

Happy to announce that I’m starting a new stage as a surgeon at @hospitalclinic de Barcelona, to continue working in multidisciplinary care for borderline and locally advanced pancreatic cancer. @ernest_hidalgo @MacarullaTeresa @olguicsMR

@US_FDA allowed @RevMedicines to initiate an EAP for daraxonrasib. Let’s fight to ensure that PDAC patients around the world also have acces to it ASAP. @ACanPan @P_C_E_ #PancreaticCancer

A Mayo Clinic-developed artificial intelligence (AI) model can help specialists detect pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis. It identifies subtle signs of disease before tumors are visible, when curative treatment may still be possible. The findings, published in Gut, mark a milestone in Mayo Clinic's multiyear research effort to enable earlier detection of one of the deadliest cancers. Learn more: mayocl.in/4eippBP

🆕#CLÍNIC-#IDIBAPS has participated in an international study that describes the antitumor activity of RAS inhibitors in preclinical models of cholangiocarcinoma, a cancer of the bile ducts associated with poor prognosis and limited treatment options 👉f.mtr.cool/jypcfxfpxy

@DrMirallas @hospitalclinic @ernest_hidalgo @MacarullaTeresa @olguicsMR Gracias Oriol! Y a ti todos los éxitos por USA!! 💪🏽

@epr82 @hospitalclinic @ernest_hidalgo @MacarullaTeresa @olguicsMR Felicidades Dra Pando! Te deseo lo mejor en @hospitalclinic @MacarullaTeresa

Happy to announce that I’m starting a new stage as a surgeon at @hospitalclinic de Barcelona, to continue working in multidisciplinary care for borderline and locally advanced pancreatic cancer. @ernest_hidalgo @MacarullaTeresa @olguicsMR

Nice preclinical & limited, promising clinical data for @RevMedicines Daraxonrasib in Bile Duct cancers (#Cholangiocarcinoma) cell.com/cancer-cell/fu… Much like in #PancreaticCancer, resistance converges on reactivation of RAS signaling via KRAS amplification or upstream SHP2.

Happening now #AACR: Phase 1 trial results for a therapeutic mRNA vaccine for pancreatic cancer, led by MSK physician-scientist Dr. @TheVinodLab, included 16 patients who received the investigational vaccine called autogene cevumeran after #pancreaticcancer surgery, along with an immunotherapy drug (called a checkpoint inhibitor) and chemotherapy. Key takeaways: 🟦 Vaccines were custom-made for each patient based on unique signatures of their tumors. 🟦 In 8 patients, the vaccine activated tumor-specific immune cells, meaning the vaccine taught the immune system to recognize tumor cells as foreign. This triggered the body to produce immune cells called T cells to target and kill the tumor cells. 🟦 Of the 8 patients whose immune system responded to the vaccine, 7 (87.5%) were still alive 4-6 years after surgery. 🟦 Among the 8 patients who didn’t respond, only 2 (25%) were still alive, with a median survival time of 3.4 years. Learn more: bit.ly/3QuIiaL @aacr

@DrMirallas @OncoAlert @Nature_NPJ @myESMO @vallhebron @ASCO @_SEOM @VHIO @hospitalclinic @yaringano_jesus @DiegoAGomez1 @OncoSantPau @hospitaldelmar @ICO_oncologia @Dr_Sepulveda_MD @mangelesvaz @H12Octubre Felicidades Oriol!

🎉 Just published @Nature_NPJ 📌 First #ESCAT for #gliomas @myESMO 🚀 Titanic effort 👥 541 🧠 🏥 8 hospitals in 🇪🇸 📉 Longer PFS&OS Tier 1&2 #ESCAT ✅ ORR 33% non-GBM ✅ ORR 17% GBM 🙏🏼 Thanks to all patients @vallhebron @OncoAlert @ASCO @_SEOM 👇🏽 pubmed.ncbi.nlm.nih.gov/41495434/

#AACR26 late breaking abstract on early data from 1st line Daraxonrasib monotherapy in #PancreaticCancer >90% disease control rate aacrjournals.org/cancerres/arti… @EileenMOReilly @GarridoLagunaMD @DrShubhamPant @RevMedicines

Great presentation from the “Queen of KRAS inhibitors” Mallika Singh @RevMedicines at #AACR26. Their portfolio of assets allows targeting of RAS in allele agnostic & allele specific manner using the tri-complex platform. The ongoing studies are all about “doubling down on RAS”.

Our latest European work on adenosquamous carcinoma of the pancreas endorsed by the @EAHPBA link.springer.com/article/10.124… @hospital_hvn @jevillarmo @Biblioteca17920 @aecirujanos @CEIHPBA

@ruthbc93 @UABBarcelona @Cirurgia_UAB @eloiespin @FVallribera @m_pera_roman Felicidades Ruth!! 👏🏻👏🏻👏🏻

Delighted to have passed my PhD viva today at @UABBarcelona @Cirurgia_UAB 🎓✨ Many thanks to my PhD directors @eloiespin & @FVallribera for their guidance and support, and to the examination board — Dra Mora, Dr @m_pera_roman & Dr Biondo — for the insightful discussion

Hoy tuvimos el honor de contar en la MasterClass de Cirugía General @vallhebron con el Dr. @flor_lorente, que compartió la experiencia de la Unidad de Exanteraciones Pélvicas de @HospitalLaFe. Ejemplo brillante de trabajo multidisciplinar y súper-especialización 🔝 @eloiespin

📣 Last call‼️ 🚀 Ready to take your career to the next level❓ 💡 8–10 fully funded PhD fellowships open for Life Sciences & Medical students! Apply now and be the next to turn cancer discoveries into cures  👉 linke.to/PhDfellowships… 📅 Deadline: 28 November #SOMMVHIO

PCE is pleased to launch the “Treatment Opportunities and Pancreatic Cancer” booklet. A clear, accessible guide to help patients and carers navigate treatment options with confidence. Download here: pancreaticcancereurope.eu/project/treatm…

@BalsellsJoaquin @vallhebron @VHIO @Ja_Capdevila A ti Joaquim, juntos construimos este proyecto del cual también debes estar orgulloso ♥️

@epr82 @vallhebron @VHIO @Ja_Capdevila Enhorabuena!!

En el día del cáncer de páncreas en @vallhebron y @vhio reafirmamos nuestro firme compromiso de dar lo mejor para nuestros pacientes. Sobretodo en los casos de máxima complejidad como localmente avanzados e irresecables. @Ja_Capdevila G.Sapisochin. vallhebron.com/es/actualidad/…

@letswinpc @PanCAN @ContraCancerEs

When excluding BRCA or PALB2 #pancreaticcancer PASS-01 shows equipoise between doublet (g/nab-p) and triplet regimens (FFX) with trend for a slight edge with gem/nab-p